Turn Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
Turn Therapeutics Inc. (TTRX), a Delaware corporation, filed a Current Report on Form 8-K dated June 1, 2026. The company is headquartered in Westlake Village, California, and its common stock trades on The Nasdaq Stock Market LLC. The registrant is classified as an emerging growth company.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a press release rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed within the text of this Form 8-K. The filing references a press release (Exhibit 99.1) issued on June 1, 2026, under Item 7.01 Regulation FD Disclosure, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information in Item 7.01 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Key Facts for Investor Verification
- Verify the content of the Press Release dated June 1, 2026, referenced as Exhibit 99.1, as the 8-K text itself contains no operational or financial details.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the filing is signed by Bradley Burnam, Chief Executive Officer.